Focused On-demand Library for Zinc finger FYVE domain-containing protein 9

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O95405

UPID:

ZFYV9_HUMAN

Alternative names:

Mothers against decapentaplegic homolog-interacting protein; Novel serine protease; Receptor activation anchor; Smad anchor for receptor activation

Alternative UPACC:

O95405; Q5T0F6; Q5T0F7; Q9UNE1; Q9Y5R7

Background:

Zinc finger FYVE domain-containing protein 9, also known as Mothers against decapentaplegic homolog-interacting protein, plays a pivotal role in early endosomal processes. It is instrumental in recruiting SMAD2/SMAD3 to intracellular membranes and the TGF-beta receptor, thereby facilitating TGF-mediated signaling. This protein's ability to regulate the subcellular location of SMAD2 and SMAD3 and modulate the transcriptional activity of the SMAD3/SMAD4 complex underscores its significance in cellular signaling pathways.

Therapeutic significance:

Understanding the role of Zinc finger FYVE domain-containing protein 9 could open doors to potential therapeutic strategies.